Interleukin-37 in Cancer Angiogenesis: Mechanisms, Therapeutic Potential, and Future Perspectives

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Interleukin-37 (IL-37), an IL-1 family member, is a potent anti-inflammatory cytokine.
• IL-37 regulates tumorigenesis, particularly angiogenesis, by suppressing pro-angiogenic signaling pathways like STAT3, Akt/mTOR, Wnt/β-catenin, and Notch.
• Reduced IL-37 expression is linked to increased tumor vascularity, advanced stages, and worse outcomes in various cancers.

Purpose of the Study:

• To investigate the role of IL-37 in regulating tumor angiogenesis and its potential as a therapeutic agent.
• To explore IL-37's impact on key signaling pathways involved in cancer progression.
• To evaluate IL-37 as a potential biomarker for cancer prognosis and treatment response.

Main Methods:

• Preclinical models involving IL-37 overexpression or administration.
• Analysis of signaling pathways (STAT3, Akt/mTOR, Wnt/β-catenin, Notch) and angiogenic factors (VEGF, HIF-1α, TSP-1).
• Clinical assessment of IL-37 levels as a biomarker.

Main Results:

• IL-37 overexpression/administration decreased VEGF and HIF-1α levels while increasing anti-angiogenic TSP-1.
• Low IL-37 levels were associated with increased tumor vessel density and advanced disease.
• Clinical data suggests low IL-37 levels may predict survival and therapeutic response.

Conclusions:

• IL-37 demonstrates therapeutic potential by modulating inflammatory and angiogenic signaling in the tumor microenvironment.
• Challenges include optimizing delivery, managing immunosuppression risks, and conducting clinical trials.
• Further research into IL-37's molecular interactions and combination therapies is crucial for clinical application.